documents (e.g., hospital discharge summary)

Step-by-Step Guide for AE Follow-Up and Resolution:

Step 1: Schedule AE Review During Subject Visit

At each subsequent visit, the clinical team should ask the subject about the status of any ongoing AEs. Lab results and vitals may also inform AE progression.

Step 2: Update eCRF with Follow-Up Details

Navigate to the AE section of the Electronic Data Capture (EDC) system. Add notes on changes in the AE’s intensity, frequency, and impact on the subject’s health.

Step 3: Record the Outcome

• Resolved: No longer present
• Ongoing: Still active
• Resolved with Sequelae: Resolved but left long-term effects
• Fatal: Led to death

Ensure this matches with site source notes and other documentation.

Step 4: Enter the Resolution Date

Capture the date the AE resolved or became stable. If the AE is ongoing at study closure, mark it accordingly in the AE form.

Step 5: Investigator Comments and Sign-Off

The Principal Investigator (PI) should provide a brief comment summarizing the AE’s progression and final status. This demonstrates that the PI reviewed the complete safety trajectory.

See Pharma SOP documentation for templates on AE follow-up visit documentation and PI review logs.

AE Follow-Up Documentation in SAEs:

If the AE was classified as a Serious Adverse Event (SAE), additional follow-up forms are often required. These include:

• SAE Follow-Up Report (submitted to sponsor)
• Updated Medical History (if new diagnosis made)
• Hospital discharge summaries or imaging reports
• Updated causality or seriousness if re-evaluated

Best Practices for AE Resolution Tracking:

• Use real-time data entry after patient visits to avoid delays
• Ensure consistency between source, eCRF, and SAE forms
• Confirm that the resolution date aligns with clinical visit timelines
• Document reason if AE is still unresolved at study end
• PI should always review and sign AE closure entries

Sites using platforms like StabilityStudies.in can integrate AE resolution workflows into their compliance checklists and audit trails.

What Monitors Look For in AE Follow-Up:

Clinical Research Associates (CRAs) reviewing follow-up data will check:

• Resolution status correctly marked in the eCRF
• Final AE end date provided and justified
• Consistency across subject notes, eCRFs, and other databases
• Appropriate supporting documentation uploaded
• Timely submission of follow-up SAE reports

Common Issues and How to Avoid Them:

• Omission of AE outcome: Always update AE record even if no change
• Unclear resolution date: If unsure, document “ongoing” and review at next visit
• Mismatch between source and eCRF: Regular cross-verification required
• Missing PI sign-off: Required for all final AE entries

Checklist for AE Resolution Documentation:

• [ ] AE follow-up reviewed at every visit
• [ ] Outcome status updated (resolved, ongoing, etc.)
• [ ] End date entered or AE marked as ongoing
• [ ] SAE follow-up report submitted (if applicable)
• [ ] Supporting documents uploaded
• [ ] PI comment and signature captured

Regulatory Expectations:

Agencies like the EMA and Health Canada require complete AE tracking, including outcome and resolution, to ensure robust pharmacovigilance. Incomplete AE documentation is one of the most common findings during GCP audits and inspections.

Conclusion:

Effective AE follow-up and resolution documentation goes beyond data entry—it’s about demonstrating your site’s diligence in protecting patient safety. By following structured workflows, maintaining data accuracy, and involving the PI in final AE review, you create a transparent, high-quality safety record that meets global regulatory standards and ensures ethical conduct in every trial.